Conflict of interest: Nothing to declare.
Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement†
Article first published online: 5 NOV 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 3, pages 500–502, March 2013
How to Cite
Franzblau, E. B., Punzalan, R. C., Friedman, K. D., Roy, A., Bilen, O. and Flood, V. H. (2013), Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatr. Blood Cancer, 60: 500–502. doi: 10.1002/pbc.24383
- Issue published online: 15 JAN 2013
- Article first published online: 5 NOV 2012
- Manuscript Accepted: 2 OCT 2012
- Manuscript Received: 11 APR 2012
- hemorrhagic disorders;
- thrombotic disorders
We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post-treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post-treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement. Pediatr Blood Cancer 2013; 60: 500–502. © 2012 Wiley Periodicals, Inc.